Your browser doesn't support javascript.
loading
Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering.
Klein, Orly R; Bonfim, Carmem; Abraham, Allistair; Ruggeri, Annalisa; Purtill, Duncan; Cohen, Sandra; Wynn, Robert; Russell, Athena; Sharma, Akshay; Ciccocioppo, Rachele; Prockop, Susan; Boelens, Jaap Jan; Bertaina, Alice.
Afiliación
  • Klein OR; Division of Hematology, Oncology and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA. Electronic address: oklein@stanford.edu.
  • Bonfim C; Pediatric Blood and Marrow Transplantation Division and Pele Pequeno Principe Research Institute, Hospital Pequeno Principe, Curitiba, Brazil.
  • Abraham A; Center for Cancer and Immunology Research, Cell Enhancement and Technologies for Immunotherapy, Children's National Hospital, Washington, DC, USA.
  • Ruggeri A; Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy.
  • Purtill D; Department of Hematology, Fiona Stanley Hospital, Perth, Australia.
  • Cohen S; Université de Montréal and Maisonneuve Rosemont Hospital, Montréal, Canada.
  • Wynn R; Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Russell A; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Ciccocioppo R; Gastroenterology Unit, Department of Medicine, Azienda Ospedaliera Universitaria Integrata Policlinico G.B. Rossi and University of Verona, Verona, Italy.
  • Prockop S; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
  • Boelens JJ; Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Pediatrics, Weill Cornell Medical College of Cornell University, New York, New York, USA.
  • Bertaina A; Division of Hematology, Oncology and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.
Cytotherapy ; 25(5): 463-471, 2023 05.
Article en En | MEDLINE | ID: mdl-36710227
Hematopoietic stem cell transplantation (HSCT) is curative for many non-malignant disorders. As HSCT and supportive care technologies improve, this life-saving treatment may be offered to more and more patients. With the development of new preparative regimens, expanded alternative donor availability, and graft manipulation techniques, there are many options when choosing the best regimen for patients. Herein the authors review transplant considerations, transplant goals, conditioning regimens, donor choice, and graft manipulation strategies for patients with non-malignant disorders undergoing HSCT.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Etiology_studies Límite: Humans Idioma: En Revista: Cytotherapy Asunto de la revista: TERAPEUTICA Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Etiology_studies Límite: Humans Idioma: En Revista: Cytotherapy Asunto de la revista: TERAPEUTICA Año: 2023 Tipo del documento: Article